Enhancers, critical determinants of cellular identity, are commonly recognized by correlative chromatin marks and gain-of-function potential, although only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously, we identified an erythroid enhancer of human BCL11A, subject to common genetic variation associated with the fetal haemoglobin level, the mouse orthologue of which is necessary for erythroid BCL11A expression. Here we develop pooled clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear to be primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction. The detailed enhancer map will inform therapeutic genome editing, and the screening approach described here is generally applicable to functional interrogation of non-coding genomic elements.
Enhancers, critical determinants of cellular identity, are commonly recognized by correlative chromatin marks and gain-of-function potential, although only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously, we identified an erythroid enhancer of human BCL11A, subject to common genetic variation associated with the fetal haemoglobin level, the mouse orthologue of which is necessary for erythroid BCL11A expression. Here we develop pooled clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear to be primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction. The detailed enhancer map will inform therapeutic genome editing, and the screening approach described here is generally applicable to functional interrogation of non-coding genomic elements.
Enhancers are classically described as distal genetic elements that positively regulate gene expression in an orientation-independent manner in ectopic heterologous gain-of-function expression experiments 1 . These elements coordinate when, where and how genes are expressed. Enhancer sequences bind transcription factors and are correlated with specific chromatin features including reduced DNA methylation, characteristic histone modifications, heightened chromatin accessibility, long-range promoter interactions, and bidirectional transcription. Recent chromatin mapping has demonstrated the abundance of distal regulatory elements bearing an enhancer signature [2] [3] [4] .
The biological importance of enhancers is underscored by gene expression studies showing the predictive power of enhancer profile on lineage-specific programs [5] [6] [7] . Highly marked and clustered enhancers (for example, so-called strong, stretch, or super-enhancers) are particularly suggestive of cellular identity and may help to infer lineage-specific regulatory factors [8] [9] [10] . Genome-wide association studies reveal enrichment of trait-associated variants in sequences bearing lineage-restricted enhancer signatures 4, 8, 11, 12 . Enhancers display signs of evolutionary constraint as well as heightened turnover with evidence of positive selection [13] [14] [15] [16] .
Despite their importance, enhancers are typically defined by criteria unrelated to in situ functional requirement. Advances in putative enhancer mapping, as well as large-scale oligonucleotide synthesis, facilitate enhancer reporter assays on a massively parallel scale, allowing a systematic evaluation of the functional significance of enhancer sequences 17, 18 . Nonetheless, ectopic heterologous enhancer assays cannot address the necessity of an element in its native chromatin environment. The growing appreciation of the nonrandom distribution of distal elements both with respect to the linear genome and within the three-dimensional nuclear environment emphasizes the importance of studying enhancers by perturbing their endogenous condition 10, 19 .
Insightful observations have been made by mutagenizing enhancers using traditional molecular genetic approaches 20, 21 ; however, the low throughput of these classical methods constrains their widespread application. Furthermore, the elevated turnover of many enhancer sequences between species may limit the ability to derive conclusions from nonhuman organisms regarding human gene regulation. Advances in genome editing technology make practical the facile modification of the human genome 22, 23 . High-throughput Cas9mediated functional genomics studies have revealed novel genes required for various biological processes [24] [25] [26] [27] . Genome editing is likewise suitable for the study of non-coding genetic elements such as enhancers, although these experiments have previously been conducted at low throughput [28] [29] [30] .
Human composite enhancer
Recently, we observed that common genetic variants associated with fetal haemoglobin (HbF; a 2 c 2 ) level and b-haemoglobin disorder clinical severity mark an adult-developmental-stage-and erythroid-lineage-specific intronic enhancer of BCL11A (ref. 28 ), a validated repressor of HbF and therapeutic target for b-haemoglobin disorders 28, [31] [32] [33] . This composite human enhancer is composed of three DNase I hypersensitive sites (DHSs), termed h155, h158 and h162 on the basis of distance in kilobases (kb) from the transcriptional start site (TSS) 28 . The most highly trait-associated haplotype is defined by two single nucleotide polymorphisms (SNPs): rs1427407 within h162 and rs7606173 within h155 (Extended Data Fig. 1a ). Previously, we showed that this enhancer possessed ectopic erythroid-restricted, adult-stage-specific enhancer activity 28 . Moreover, the mouse orthologue of the composite enhancer-defined by primary sequence homology, shared erythroid enhancer chromatin signature and syntenic position relative to coding sequenceswas shown to be required for BCL11A expression and embryonic globin gene repression in a mouse erythroid cell line but dispensable in a mouse B-lymphoid cell line 28 .
To evaluate the requirement for human BCL11A enhancer sequences, we used HUDEP-2 cells, an immortalized human CD34 1 haematopoietic stem and progenitor cell (HSPC)-derived erythroid precursor cell line that expresses BCL11A and predominantly brather than c-globin 34 . We used the CRISPR-Cas9 nuclease system to generate clones of HUDEP-2 cells with deletion of the 12-kb BCL11A composite enhancer by introduction of a pair of chimaeric single guide RNAs (sgRNAs). Enhancer deletion resulted in near-complete loss of BCL11A expression and induction of c-globin and HbF protein to similar levels as cells with BCL11A knockout (Fig. 1a-c) , consistent with the possibility that these sequences could serve as targets for therapeutic genome editing for HbF reinduction for the b-haemoglobinopathies 35 . Although targeted deletions by paired double strand breaks (DSBs) may be achieved by genome editing, competing genomic outcomes include local insertion/deletion (indel) production at each cleavage site as well as inversion of the intervening segment 22, 23, [36] [37] [38] .
Tiled pooled enhancer editing in situ
We hypothesized that composite enhancers may be composed of a functional hierarchy with essential and dispensable constituent components. A functional hierarchy might enable enhancer disruption by a single DSB at a critical region followed by non-homologous end joining (NHEJ) repair with indels. In fact, the hypothesis that a prevalent mechanism of trait associations is enhancer variation rests on the premise that single nucleotide changes themselves may substantively modulate enhancer function. Therefore, we reasoned that a tiling set of sgRNAs could uncover critical enhancer regions by disruption of nearly all sequences within an enhancer on the basis of the typical outcome of Cas9 cleavage and NHEJ repair, an indel spectrum with frequent deletions of up to 10 base pairs (bp) from the cleavage position 22, 23, 36, 38, 39 .
We designed all possible sgRNAs within the human BCL11A composite enhancer DHSs ( Fig. 1d , e) as restricted only by the presence of the Streptococcus pyogenes Cas9 (SpCas9) NGG protospacer adjacent motif (PAM) sequence, which restricts cleavage at an average 1/8 frequency at each genomic position 22, 39 . The NGG-PAM-restricted sgRNAs had a median gap between adjacent genomic cleavages of 4 bp and 90th percentile of 18 bp ( Fig. 1f ), which suggested that this strategy could approach saturation mutagenesis in situ. We included non-targeting sgRNAs as negative controls as well as sgRNAs tiling exon 2 of BCL11A as positive controls (Fig. 1e ). The library was successfully cloned to a lentiviral vector. The basic experimental schema was to transduce HUDEP-2 cells with the lentiviral library at low multiplicity such that nearly all selected cells contained a single integrant ( Fig. 1d ). After expansion, differentiation, sorting by HbF level, genomic DNA isolation and deep sequencing of integrated sgRNAs, an HbF enrichment score was calculated for each sgRNA by comparing its representation in HbF-high and HbF-low pools (see Supplementary Information and Extended Data Fig. 2 for additional technical details).
We mapped the HbF enrichment score of each sgRNA to its predicted position of genomic cleavage ( Fig. 2a ). Most enhancer targeting sgRNAs showed no significant enrichment or depletion from the HbF-high pool. The enriching sgRNAs co-localized to discrete genomic positions. For example, we observed a cluster of sgRNAs at h162 with modest enrichment, a cluster at h155 with moderate enrichment (as well as adjacent clusters with depletion), and a cluster at h158 with marked enrichment. Of note, we observed ten sgRNAs at h158 with cleavage positions within 42 bp each with HbF enrichment scores exceeding 0.99, the median enrichment score of BCL11A exon-2-targeting sgRNAs.
Exon-2-targeted sgRNAs showed a linear correlation between HbF enrichment and cellular dropout, suggesting that sgRNAs that result in complete knockout of BCL11A lead to a reduced rate of cell accumulation inseparable from HbF derepression ( Fig. 2b) . In contrast, the sgRNAs at h158 associated with marked HbF enrichment showed blunted impact on dropout (Fig. 2b ). This finding could be consistent with a low residual level of BCL11A adequate to promote cellular accumulation but inadequate to suppress HbF.
To corroborate these findings, we introduced two sgRNAs to the HUDEP-2/Cas9 cells to produce targeted deletion or inversion clones 36 . Deletion of h158 phenocopied deletion of the composite enhancer and deletion of h155 had moderate effect (while deletion of h162 showed a non-significant trend towards a modest effect), consistent with the magnitude of top-scoring and co-localizing sgRNAs from the screen (Fig. 2a , c-e). Inversion of the h158 or h155 sites had no significant effect on gene expression, demonstrating that the BCL11A enhancer functions in an orientation-independent manner in situ, consistent with the classic enhancer definition 1 (Fig. 2c-e ). 
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To validate the findings from the HUDEP-2 cells, the top-scoring enhancer-targeting sgRNA from the screen (number 1621 at h158) was tested in primary human erythroblasts by lentiviral transduction of human CD34 1 HSPCs exposed to ex vivo erythroid culture conditions. Consistent with the screen results, sgRNA-1621 resulted in downregulation of BCL11A expression and corresponding upregulation of c-globin expression and increase in HbF 1 cells ( Fig. 2f-h) . Notably, sgRNA-1621 did not alter surface marker profile, enucleation frequency, or cellular morphology (Extended Data Fig. 3c ). Together, these results suggest proof-of-principle of an individual sgRNA targeting a non-coding element for therapeutic genome editing of b-haemoglobin disorders.
Primate-specific enhancer sequences
We applied a hidden Markov model (HMM) to the sgRNA enrichment score data to infer functionally important sequences within each DHS (Extended Data Fig. 4a ). This model defined three functional states-active, repressive and neutral-based on likelihood to encompass sequences that positively, negatively and neutrally regulate target gene expression, respectively. The model identified functional states within each DHS ( Fig. 3a-c) . At each of the three DHSs, the active states were precisely located at regions with the highest degree of DNase I sensitivity.
The overall sequence conservation at the h158 active region appears both less intense and less distinct from flanking sequences as compared to those of h162 and h155 ( Fig. 3a-c) . The top-scoring sgRNAs in the screen co-localize to 42 bp within h158 ( Fig. 4 and Extended Data Fig. 5b ). The third-highest-scoring enhancer-targeted sgRNA (sgRNA-1617) mapped directly onto an apparent GATA1 motif, although below a genome-scale significance threshold (P 5 3.74 3 10 24 ). The mouse orthologous sequence has a GATA1 motif P value only modestly higher than has the human (P 5 4.33 3 10 24 ). This GATA1 motif appears to have relatively high vertebrate conservation, with exact human sequence identity in rabbits, pigs, dogs and elephants. The top-scoring sgRNA (sgRNA-1621) mapped to a position 15 bp from this GATA1 motif ( Fig. 4 ). An additional four sgRNAs mapping between sgRNA-1621 a-c, HMM segmentation of functional enhancer states. HbF enrichment scores are shown throughout DHSs h155, h158 and h162 by grey lines and circles, with the blue line representing smoothed enrichment score. DNase I sequencing from primary human erythroblasts 28 . PhyloP (scale from 24.5 to 4.88) and PhastCons (from 0 to 1) estimates of evolutionary conservation among 100 vertebrates are shown. Positions of SNPs rs7606173 and rs1427407 are denoted, which together define the haplotype most highly associated with HbF level 28 . and sgRNA-1617 each had substantially elevated HbF enrichment scores. Underlying these sgRNAs were additional predicted motifs (that is, RXRA, EHF, ELF1 and STAT1). Although these sequences showed a high level of conservation among primates, they showed high degeneracy among nonprimate vertebrates ( Fig. 4) .
We tested the pattern of mutations observed upon treatment of cells with either sgRNA-1621 or sgRNA-1617 by deep sequencing. Each of these sgRNAs is sufficient to substantially induce HbF in human erythroid cells ( Fig. 2h and Extended Data Fig. 3a, b ). We sorted cells exposed to Cas9 and these sgRNAs into HbF-high and HbF-low pools. We determined the indel spectrum in each population by deep sequencing (Extended Data Fig. 4b ). As expected, we observed indels clustering around the predicted cleavage positions. By comparing the per nucleotide indel ratio between cells from the HbFhigh and HbF-low pools, we calculated a relative indel enrichment across the sequencing amplicon. Notably, both sgRNAs yielded maximal HbF indel enrichment not precisely at the expected cleavage position but offset at shared intervening sequences ( Fig. 4 ). These sites of maximal HbF mutation enrichment mapped to 7 bp directly overlapping predicted motifs ( Fig. 4 ). Taken together, these data suggest that a conserved GATA1 motif scoring below the prediction threshold adjacent to primate-specific sequences form the core of an enhancer essential for human erythroid BCL11A expression and HbF repression.
Mouse enhancer dissection
To test functional conservation of the BCL11A enhancer, we examined the orthologous mouse Bcl11a enhancer in greater detail. Erythroid DNase I sensitivity is observed at those sequences homologous to h155 and h162 but not h158 (Extended Data Fig. 6a ), consistent with the reduced sequence homology within the h158 active region ( Fig. 3a-c ). We performed a pooled CRISPR enhancer saturating mutagenesis screen in MEL ey:mCherry reporter cells, similar to the human screen described above (Extended Data Figs 6 and 7, and Supplementary Information).
Upon mapping the sgRNA cleavage positions to the genome, we again observed that the majority of enhancer-targeting sgRNAs demonstrated no significant ey enrichment or depletion. We observed co-localization of sets of sgRNAs with ey enrichment (Fig. 5a ). There was a similar complex pattern at the m155 orthologue as at h155, with adjacent regions with enriching and depleting sgRNAs from the high-ey:mCherry pool at the DHS core. At the m158 orthologue we did not observe any evidence of ey enriching or depleting sgRNAs. At the m162 orthologue there was a marked peak, with five sgRNAs with ey enrichment scores exceeding 1.30, the median enrichment score of Bcl11a exon-2-targeting sgRNAs (Fig. 5a ). This potent impact of the m162 orthologue was in contrast to the modest impact of individual sgRNAs or DHS deletion at h162.
We used pairs of sgRNAs in the presence of Cas9 to produce MEL clones with deletions of various substituent elements at the Bcl11a enhancer ( Fig. 5b ). Deletion of the DNase-insensitive m158 orthologue had no apparent effect on Bcl11a expression, consistent with the pooled screen result. Deletion of the m155 orthologue led to an approximately twofold reduction in Bcl11a expression (mean Error bars represent s.e.m.
ARTICLE RESEARCH residual level 49%, P , 0.0001), whereas deletion of the m162 orthologue approached deletion of the entire composite enhancer in terms of reduction in Bcl11a expression (mean residual levels of 8% (P , 0.0001) and 6% (P , 0.0001), respectively, Fig. 5b ; also see Supplementary Information and Extended Data Figs 8 and 9 ). In addition, clones in which the m162 orthologue was inverted showed no change in Bcl11a expression, suggesting that the mouse enhancer, like the human enhancer, functions independently of orientation in situ (Figs 2c-e and 5b).
Erythroid-restricted function in vivo
To substantiate the importance of the m162 orthologue for Bcl11a expression and to validate BCL11A enhancer disruption as a therapeutic strategy, we generated mice deficient for the Bcl11a m162 orthologue. We used the same Cas9 and paired sgRNA deletion strategy in mouse embryonic stem cells, from which we derived mice with germline transmission of the enhancer deletion. Previous studies have demonstrated essential roles for Bcl11a in structural development of the central nervous system and B lymphopoiesis [40] [41] [42] . Notably, unlike conventional Bcl11a knockouts, which die hours after birth, m162 orthologue deletion mice were born healthy at expected Mendelian ratios (Extended Data Fig. 10a ). The m162 orthologue deletion mice also showed normal frequencies of B-cell progenitors in the fetal liver and mature B lymphocytes in the adult peripheral blood (Extended Data Fig. 10b , c). Other haematopoietic lineages were also observed at wild-type frequencies (Extended Data Fig. 10c ). Bcl11a expression was unperturbed in the brain or sorted B cell precursors from embryonic day 16.5 (E16.5) embryos (Extended Data Fig. 10d ). In contrast, there was substantial reduction in Bcl11a levels in sorted E16.5 erythroid precursors (26% residual, P , 0.05; Extended Data Fig. 10d ). The m162 orthologue deletion mice were bred to mice transgenic for the human b-globin cluster (b-YAC) to model the role of BCL11A in haemoglobin switching 43 . Unlike its fetal-stage expression in humans, in the mouse fetal liver transgenic human c-globin is subject to intense repression (like an embryonic globin). Bcl11a is required for this early murine silencing of transgenic c-globin at E14.5, although even in the absence of Bcl11a, c-globin is ultimately repressed 32, 33 . Fetal livers were evaluated between days E12.5 and E18.5 to monitor haemoglobin switching. Repression of human c-globin and activation of human b-globin was markedly delayed in the m162 orthologue deleted mice ( Fig. 5c ). Heterozygous mice showed an intermediate c-globin derepression phenotype, underscoring the dose-dependent inverse relationship between BCL11A and HbF level. These results indicate that targeting the erythroid enhancer of Bcl11a in vivo results in erythroid-specific disruption of Bcl11a expression and relaxed repression of c-globin, unaccompanied by the obvious neurological and immunological toxicities seen in the Bcl11a conventional knockout context.
Discussion
We employed a novel application of CRISPR-Cas9 genome editing, saturating mutagenesis of non-coding elements in situ, to provide an important insight into the organization and function of the BCL11A erythroid enhancer. Traditional tests of enhancer function rely on ectopic heterologous reporter assays and/or correlative biochemical features. Genome editing allows facile evaluation of the requirement of enhancer sequences within their endogenous chromatin context for appropriate gene regulation. As shown here, high-resolution, high-throughput pooled tiling sgRNA screening reveals underlying enhancer sequence requirements approaching nucleotide resolution. A limitation to the resolution of this approach is the availability of NGG PAM sequences in a given region. We did not observe efficient editing by SpCas9 with NAG-restricted sgRNAs (Extended Data Figs 2h and 6j). Recent studies have identified Cas9 orthologues and variants restricted by alternative PAM sequences, each capable of efficient genome editing [44] [45] [46] . This increased targeting range of Cas9 could allow increased resolution for in situ mutagenesis, particularly at sequences with paucity of NGG motifs. Alternatively, approaches reliant on homology-directed repair 47 could offer nucleotide-resolution functional mutagenesis of non-coding sequences, although issues of efficiency, fidelity and quantitative sensitivity would need to be considered. We suggest that our tiled pooled CRISPR screening approach could be readily adapted to the functional interrogation of numerous non-coding genomic elements.
In addition, these data demonstrate that apparent sequence conservation at the BCL11A enhancer masks underlying functional divergence. The mouse and human BCL11A erythroid composite enhancers share primary sequence homology, an erythroid enhancer chromatin signature, and syntenic intronic position relative to coding sequences. Moreover, both are required for erythroid expression of BCL11A and repression of embryonic/fetal globin genes. However, our high-resolution CRISPR mutagenesis analysis reveals divergence in the architecture of these enhancers. Of note, human BCL11A enforces the cto b-globin developmental switch around the time of birth. The timing and nature of these switches and the globin genes themselves are distinct in primates as compared to nonprimate vertebrates that only exhibit a mid-gestation embryonic to adult switch 48 . Therefore, it would seem plausible that critical regulatory mechanisms at BCL11A might differ between species (also see Supplementary Information).
The haemoglobin disorders are among the most common Mendelian inherited human conditions. The level of HbF is a key modifier of clinical severity of these diseases and BCL11A is the chief regulator of HbF level 48 . Naturally occurring genetic variation at the BCL11A enhancer is well-tolerated and associated with HbF level and b-haemoglobin disorder clinical severity. The work presented here offers a framework for therapeutic genome editing of the BCL11A enhancer for b-haemoglobin disorders. Enhancer disruption by individual sgRNAs in primary erythroid precursors results in substantial HbF induction. This approach may mitigate erythroid-specific growth disadvantages of complete BCL11A loss ( Fig. 2b ). Furthermore, erythroid enhancer disruption may spare BCL11A expression and function in non-erythroid contexts, such as B lymphopoiesis (Extended Data Fig. 10b-d) . A challenge for the field is that it is not yet possible to accurately model HbF repression experimentally. However, individuals haploinsufficient for BCL11A due to microdeletions exhibit marked neurological deficits, and elevated HbF beyond that seen in homozygotes for high-HbF common enhancer haplotypes 49, 50 . Taken together, these data suggest that perturbation of critical sequences within the BCL11A enhancer defined here may result in HbF levels exceeding a clinical threshold required to ameliorate the b-haemoglobin disorders. 
METHODS
No statistical methods were used to predetermine sample size. Generation of genomic deletions in HUDEP-2 cells. HUDEP clone 2 (HUDEP-2) was used as previously described 34 . HUDEP-2 cells were expanded in StemSpan SFEM (Stem Cell Technologies) supplemented with 10 26 M dexamethasone (Sigma), 100 ng ml 21 human stem cell factor (SCF) (R&D), 3 international units (IU) ml 21 erythropoietin (Amgen), 1% L-glutamine (Life Technologies), and 2% penicillin/streptomycin. 1 mg ml 21 doxycycline (Sigma) was included in the culture to induce expression of the human papilloma virus type 16 E6/E7 genes 34 . HUDEP-2 cells were differentiated in Iscove's Modified Dulbecco's Medium (IMDM) (Life Technologies) supplemented with 330 mg ml 21 holo-transferrin (Sigma), 10 mg ml 21 recombinant human insulin (Sigma), 2 IU ml 21 heparin (Sigma), 5% human solvent detergent pooled plasma AB (Rhode Island Blood Center), 3 IU ml 21 erythropoietin, 100 ng ml 21 human SCF, 1 mg ml 21 doxycycline, 1% L-glutamine, and 2% penicillin/streptomycin. Tandem sgRNA lentiviruses were transduced into HUDEP-2 with stable Cas9 expression ( Supplementary Table 1 ). Bulk cultures were incubated for 7-10 days with 10 mg ml 21 blasticidin and 1 mg ml 21 puromycin selection to allow for editing. Then bulk cultures were plated clonally at limiting dilution. 96 well plates with greater than 30 clones per plate were excluded to avoid mixed clones. After approximately 14 days of clonal expansion, genomic DNA was extracted using 50 ml QuickExtract DNA Extraction Solution per well (Epicentre). Clones were screened for deletion by conventional PCR with one PCR reaction internal to segment to be deleted (non-deletion band) and one gap-PCR reaction across the deletion junction (deletion band) that would only amplify in the presence of deletion 36 . Biallelic deletion clones were identified as the absence of the nondeletion PCR band and the presence of the deletion PCR band (Supplementary Table 2 ). Inversion clones were identified as previously described by PCR 36 ( Supplementary Table 3 ). Briefly, inversion clones had one inverted allele and one deleted allele without the presence of non-deletion alleles. In our experience biallelic inversion clones are very rare events 36 . PCR was performed using the Qiagen HotStarTaq 23 master mix and the following cycling conditions: 95 uC for 15 min; 35 cycles of 95 uC for 15 s, 60 uC for 1 min, 72 uC for 1 min; 72 uC for 10 min. Alternatively, PCR was also performed using 23 Accuprime Supermix II (Life Technologies) with the following cycling conditions: 94 uC for 2 min; 35 cycles of 94 uC for 20 s, 60 uC for 20 s, 68 uC for 1 min kb 21 of PCR product; 68 uC for 5 min. RNA was extracted from each positive clone using a kit (Qiagen) and quantitative real-time RT-qPCR was performed using iQ SYBR Green Supermix (Bio-Rad). Primers used are found in Supplementary Table 5 . Gene expression was normalized to that of GAPDH. We isolated four control, one BCL11A null, three composite enhancer deleted, one h155 deleted, one h158 deleted, five h162 deleted, three h155 inverted, and two h158 inverted clones. The BCL11A null clone had a 216 bp interstitial deletion of exon 2, preventing binding of the RT-qPCR primers. All gene expression data reported from these clones represents the mean of at least three technical replicates. Design and synthesis of human and mouse lentiviral sgRNA libraries. Every 20-mer sequence upstream of an NGG or NAG PAM sequence on the plus or minus strand was identified for both the human and mouse orthologous 155, 158 and 162 DHS as well as BCL11A/Bcl11a exon 2 ( Fig. 1 and Extended Data Figs 2, 6). Relative to the human hg19 reference genome, a reference was used with the following substitutions to approximate a common low-HbF-associated haplotype: rs1427407-G, rs1896293-T, rs6706648-T, rs6738440-G, rs7606173-C. The mouse orthologous sequences to each of the human DHSs were defined by using the liftOver tool of UCSC Genome Browser as previously described 28 . Each of the sgRNA oligos were synthesized as previously described 25, 51, 52 and cloned using a Gibson Assembly master mix (New England Biolabs) into lentiGuide-Puro (Addgene plasmid ID 52963) which had been BsmBI digested, gel purified, and dephosphorylated. Gibson Assembly products were transformed to electrocompetent cells (E. cloni, Lucigen). Sufficient colonies were isolated to ensure ,903 library coverage for both human and mouse libraries. Plasmid libraries were deep sequenced to 5333 and 8133 coverage for human and mouse libraries, respectively, to confirm representation.
To produce lentivirus, HEK293T cells were cultured with Dulbecco's Modified Eagle's Medium (DMEM) (Life Technologies) supplemented with 10% fetal bovine serum (FBS) (Omega Scientific) and 2% penicillin-streptomycin (Life Technologies) in 15 cm tissue culture treated Petri dishes. HEK293T cells were transfected at 80% confluence in 12 ml of media with 13.3 mg psPAX2, 6.7 mg VSV-G, and 20 mg of the lentiviral construct plasmid of interest using 180 mg of linear polyethylenimine (Polysciences). Medium was changed 16-24 h after transfection. Lentiviral supernatant was collected at 48 and 72 h post-transfection and subsequently concentrated by ultracentrifugation (24,000 rpm for 2 h at 4 uC with Beckman Coulter SW 32 Ti rotor).
Tiled pooled CRISPR-Cas9 screen for in situ functional mapping the human BCL11A erythroid enhancer. HUDEP-2 cells with stable Cas9 expression were transduced at low multiplicity with the human sgRNA library lentivirus pool while in expansion medium. Control transductions were performed to ensure transduction rate did not exceed 50%. Cell numbers were maintained throughout the experiment at levels adequate to exceed 1,0003 representation of the library. 10 mg ml 21 blasticidin (Sigma) and 1 mg ml 21 puromycin (Sigma) were added 24 h after transduction to select for lentiviral library integrants in cells with Cas9. Cells were cultured in expansion media for one week followed by differentiation media for an additional week.
Intracellular staining was performed by fixing cells with 0.05% glutaraldehyde (grade II) (Sigma) for 10 min at room temperature. Cells were centrifuged for 5 min at 600g and then resuspended in 0.1% Triton X-100 (Life Technologies) for 5 min at room temperature for permeabilization. Triton X-100 was diluted with phosphate buffered saline (PBS) with 0.1% BSA and then centrifuged at 600g for 15 min. Cells were stained with anti-human antibodies for HbF (clone HbF-1 with FITC or APC conjugation; Life Technologies) and b-haemoglobin antibody (clone 37-8 with PerCP-Cy5 or PE conjugation; Santa Cruz) for 20 min in the dark. Cells were washed to remove unbound antibody before FACS analysis. 0.2 mg HbF and 2 mg of adult haemoglobin (HbA) (b-haemoglobin) antibodies were used per 5 million cells. Control cells exposed to a non-targeting sgRNA sample and BCL11A exon 2 were used as negative and positive controls, respectively, to establish flow cytometry conditions. Populations of cells with the top and bottom 10% of expression of HbF were sorted by FACS.
After sorting the HbF-high and HbF-low pools, library preparation and deep sequencing was performed as previously described 25 . Briefly, genomic DNA was extracted using the Qiagen Blood and Tissue kit. Herculase PCR reaction (Agilent) using lentiGuide-Puro specific primers (59-AATGGACTATCATA TGCTTACCGTAACTTGAAAGTATTTCG-39 and 59-CTTTAGTTTGTAT GTCTGTTGCTATTATGTCTACTATTCTTTCCC-39) including a handle sequence was performed as follows: Herculase II reaction buffer (13), forward and reverse primers (0.5 mM each), dimethyl sulfoxide (DMSO) (8%), deoxynucleotide triphosphates (dNTPs) (0.25 mM each), Herculase II Fusion DNA Polymerase (0.5 reactions) using the following cycling conditions: 95 uC for 2 min; 20 cycles of 95 uC for 15 s, 60 uC for 20 s, 72 uC for 30 s; 72 uC for 5 min. Multiple reactions of no more than 200 ng each were used to amplify from 6.6 mg gDNA (,1310 6 cell genomes) per pool. Samples were subjected to a second PCR using handle-specific primers 25 to add adaptors and indexes to each sample using the following conditions: Herculase II reaction buffer (13), forward and reverse primers (0.5 mM each), dNTPs (0.25 mM each), Herculase II Fusion DNA Polymerase (0.5 reactions) with the following cycling conditions: 95 uC for 2 min; 25 cycles of 95 uC for 15 s, 60 uC for 20 s, 72 uC for 30 s; 72 uC for 5 min. PCR products were run on an agarose gel and the band of expected size was gel purified. Illumina MiSeq 150 bp paired end sequencing was performed.
sgRNA sequences present in the plasmid pool as well as in the HbF-high and HbF-low pools were enumerated. Guide sequences were mapped to the guides comprising the sgRNA library without allowing mismatches. Total reads were normalized to library sequencing depth. Cellular dropout score was determined by calculating (1) the ratio of normalized reads in the cells at end of experiment (average of reads in the HbF-high and HbF-low pools) to reads in the plasmid pool; (2) log 2 transformation; and (3) median of biological replicates. HbF enrichment score was determined by calculating (1) the ratio of normalized reads in the HbF-high compared to reads in the HbF-low pools; (2) log 2 transformation; and (3) median of biological replicates. After exclusion of sgRNAs with dropout scores ,2 23 and NAG PAM sgRNAs, a quantile-quantile plot was made with a line fitted through the first and third quantiles using R software. HbF enrichment scores and cellular dropout scores were compared by Spearman rank correlation. sgRNA sequences were mapped to the human genome (hg19) with cleavage positions set to between positions 17 and 18 given PAM positions 21-23. For visual comparisons to targeting sgRNAs, non-targeting sgRNAs were pseudomapped each separated by 5 bp. Validation in primary human CD34 1 HSPCs. Primary human CD34 1 HSPCs from G-CSF mobilized healthy adult donors were obtained from the Center of Excellence in Molecular Hematology at the Fred Hutchinson Cancer Research Center, Seattle, Washington. CD34 1 HSPCs were subject to erythroid differentiation liquid culture as previously described 53 . Briefly, HSPCs were thawed on day 0 into erythroid differentiation medium (EDM) consisting of IMDM supplemented with 330 mg ml 21 holo-human transferrin, 10 mg ml 21 recombinant human insulin, 2 IU ml 21 heparin, 5% human solvent detergent pooled plasma AB, 3 IUml 21 erythropoietin, 1% L-glutamine, and 2% penicillin/streptomycin. During days 0-7 of culture, EDM was further supplemented with 10 26 M hydrocortisone (Sigma), 100 ng ml 21 human SCF, and 5 ng ml 21 human IL-3 (R&D).
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During days 7-11 of culture, EDM was supplemented with 100 ng ml 21 human SCF only. During days 11-18 of culture, EDM had no additional supplements.
HSPCs were transduced with lentiCas9-Blast (Addgene plasmid ID 52962) 24 h after thawing in the presence of 10 mM 16,16-dimethylprostaglandin E2 (PGE2; Cayman Chemical). At 48 h after thawing, medium was changed and cells were transduced with lentiGuide-Puro or lentiGuide-Crimson cloned with relevant sgRNA sequence in the presence of 10 mM PGE2. Three independent transductions were performed per sgRNA. At 72 h after thawing, medium was changed and HSPCs were selected with 10 mg ml 21 blasticidin and 1 mg ml 21 puromycin or 10 mg ml 21 blasticidin followed by sorting for lentiGuide-Crimson 1 cells on day 16 of culture. Blasticidin and/or puromycin selection occurred from days 3 to 8 of culture.
Differentiation was assessed on day 18 of culture using anti-human antibodies against the transferrin receptor (CD71) (Clone OKT9 with FITC conjugation; eBioscience) and glycophorin A (CD235a) (Clone HIR2 with PE conjugation; eBioscience). Enucleation was assessed using 2 mg ml 21 of the cell-permeable DNA dye Hoescht 33342 (Life Technologies). CD235a 1 Hoescht 33342 2 cells were determined to be enucleated erythroid cells. Cells were intracellularly stained for HbF and HbA on day 18 of culture as described above. 50,000-100,000 cells were centrifuged onto microscope slides at 350 rpm for 4 min. Slides were stained with Harleco May-Grünwald stain (Millipore) for 2 min, Giemsa stain (Sigma) for 12 min, and two water washes for 30 s each. Slides were air dried and then coverslipped using Fisher Chemical Permount Mounting Medium (Fisher). RNA isolation and RT-qPCR was performed as above. Gene expression was normalized to that of GAPDH. All gene expression data represent the mean of at least three technical replicates.
PCR primers were designed to amplify the genomic cleavage site for a given sgRNA. Resulting PCR products were subjected to Sanger sequencing. Sequencing traces were used for editing quantification using a previously described publically available tool 54 . Computational analysis. Human erythroid H3K27ac ChIP-seq was obtained from Xu et al. 7 and mouse erythroid H3K27ac ChIP-seq was obtained from Kowalczyk et al. 55 and Dogan et al. 56 . We uniformly processed all the data sets using the same pipeline with the same criteria to call super-enhancers. Specifically, we started from raw reads and realigned each data set with Bowtie2 with the default parameters. We then removed duplicate reads with the Picard Suite. To call the peaks we used MACS2 in the narrow mode. Finally, to call the super-enhancers we used the ROSE algorithm with the default parameters 10 . Using these settings, peaks closer than 12.5 kb are stitched together and then ranked based on the H3K27ac intensity. To assign super-enhancers to genes we used again ROSE with default settings. In particular, the tool reports three categories of genes for each superenhancer: (1) overlapping genes (genes for which the gene body region overlaps a super-enhancer); (2) proximal genes (genes close to a super-enhancer considering a window of 50 kb); (3) closest gene (closest gene considering its TSS and the centre of the super-enhancer). To generate a Venn diagram of genes for super-enhancer data sets, we used the union of these three gene categories.
HMM segmentation was performed to automatically segment the enrichment score signals into enhancer regions with active, repressive and neutral effect. We designed a HMM with 3 states using the GHMM package (http://ghmm.sourceforge.net/). To learn the HMM parameters we used the Baum-Welch algorithm. To find the best segmentation for each region we used the Viterbi algorithm. The emission probability for each state was modelled as a Gaussian distribution and all the possible transitions between states were allowed as shown in Extended Data Fig. 4a . Since the signal was not obtained with a constant genomic resolution, we interpolated and smoothed the signal using a Gaussian kernel over 12 bp and applied the HMM to the smoothed signal. To set the initial parameters, we used the 1%, 50% and 99% percentile of the smoothed signal for the prior of the means of the repressive, neutral and active states, respectively, while the prior for the standard deviation was set to 0.001 for all the three states.
Motif analysis was performed to evaluate the human and mouse enhancer regions for potential binding sites for known transcription factors. We used the FIMO software 57 with a P-value threshold of ,10 24 . For each region we extracted sequences using the hg19 and mm9 assemblies respectively for human and mouse. The motif database was the latest version of the JASPAR database 58 .
Deep sequencing paired-end reads of genomic amplicons from genome editing target sites were first filtered for reads with PHRED quality score ,30, merged with the FLASH (Fast Length Adjustment of SHort reads) software, and subsequently aligned to a reference amplicon using the needle aligner from the EMBOSS suite (http://emboss.sourceforge.net/) to quantify insertions and deletions. Per nucleotide frequency of deletion of a position, insertion directly adjacent to the position, or no mutation at the position was quantitated using CRISPResso (https://github.com/lucapinello/CRISPResso).
Pooled CRISPR-Cas9 screen for high-resolution functional mapping of mouse Bcl11a enhancer. Murine erythroleukaemia (MEL, MEL-745A cl. DS19) cells were cultured in DMEM supplemented with 10% FBS, 1% L-glutamine, and 2% penicillin/streptomycin as previously described 28, 36 . Cell lines tested negative for mycoplasma contamination. ey:mCherry reporter MEL cells with stable Cas9 expression were transduced at low multiplicity with the mouse sgRNA library lentivirus pool (see Supplementary Information and Extended Data Fig. 6 for additional technical details). Control transductions were performed to ensure that the transduction rate did not exceed 50%. Cell numbers were maintained throughout the experiment at levels adequate to exceed 1,0003 representation of the library. 10 mg ml 21 blasticidin and 1 mg ml 21 puromycin were added 24 h after transduction to select for lentiviral library integrants in cells with Cas9. Subsequently cells were cultured for 2 weeks. The top and bottom 5% of ey-mCherry-expressing cells exposed to the library were sorted by FACS. A non-targeting sgRNA sample was used as a negative control and Bcl11a exon 2 as a positive control to establish flow cytometry conditions. After sorting, library preparation and deep sequencing were performed as described for the human library 25 .
sgRNA sequences present in the Hbb-ey:mCherry-high and Hbb-ey:mCherrylow pools were enumerated. Cellular dropout and ey enrichment scores were calculated analogously to the human screen. sgRNA sequences were then mapped to the mouse genome (mm9). Generation of genomic deletions in MEL cells. Deletions in MEL cells were generated using two sgRNA as previously described 36 . Briefly, sgRNA sequences were cloned into pX330 (Addgene plasmid ID 42230) using a Golden Gate assembly cloning strategy (Supplementary Table 1 ). MEL cells were electroporated with 5 mg of each pX330-sgRNA plasmid and 0.5 mg pmax-GFP (Lonza) in BTX electroporation buffer using a BTX electroporator (Harvard Apparatus). Approximately 48 h post-electroporation, the top 1-3% of GFP 1 cells were sorted and plated clonally at limiting dilution. Clones were allowed to grow for 7-10 days. Clones were screened for deletion by conventional PCR using the same strategy as with the HUDEP-2 cells ( Supplementary Tables 2 and 4 ). Inversion clones were identified by PCR as previously described 36 (Supplementary Table 3 ). Generation of genomic deletions in mouse embryonic stem cells (mESCs). mESCs were maintained on irradiated mouse embryonic fibroblasts (GlobalStem) and cultured in high glucose DMEM supplemented with 15% FBS, 1% L-glutamine, 2% penicillin/streptomycin (Life Technologies), 100 mM non-essential amino acids (Life Technologies), 1% nucleosides (Sigma), 10 24 M b-mercaptoethanol (Sigma), and 10 3 U ml 21 leukaemia inhibitory factor (Millipore). Cells were passaged using 0.25% trypsin (Life Technologies).
The Bcl11a 162 deletion mice were derived from CRISPR-Cas9 modified CJ9 ES cells. Using Amaxa ES Cell transfection reagent (Lonza), two million mESCs were electroporated with 2 mg of each pX330 plasmid vector containing individual target sequences flanking the 162 site along with 0.5 mg of a GFP plasmid. After 48 h, the top 5% of GFP expressing cells were sorted, plated on irradiated fibroblasts and maintained. Individual ES cell colonies were then picked and screened for biallelic deletion using the same strategy as HUDEP-2 and MEL cells 36 . DNA for screening CRISPR-Cas9 modified clones was obtained from gelatin adapted ES cell clones to avoid genomic contamination from the fibroblasts. Correctly targeted clones with greater than 80% normal karyotype were used to generate mice. Clones were injected into embryonic day 3.5 (E3.5) C57BL/ 6 blastocysts and implanted into pseudo-pregnant females.
The b-YAC mouse line (A20), previously described as containing a transgene encompassing ,150 kb of the human b-globin locus 43 , was used to analyse human globin expression. The mouse line was maintained in a hemizygous state and bred with Bcl11a 162 deletion mice. Sufficient matings were established to ensure adequate homozygotes for analysis. Mouse cell and tissue analysis. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. For developmental haematopoiesis, fetal liver cells were taken at E12.5, E14.5, E16.5 and E18.5 and mechanically dissociated to form single cell suspensions from which RNA was extracted using the RNeasy Plus Mini Kit (Qiagen) and analysed. At E16.5, fetal livers were also stained with CD19-PerCP-Cy5.5 (Clone 1D3; eBioscience), B220-APC (RA3-6B2; Biolegend), CD71-PE (Clone C2; BD Biosciences), and Ter119-FITC (Clone Ter119; BD Biosciences) to isolate B cells (B220 1 CD19 1 ) and erythroid cells (Ter119 1 CD71 1 ) by FACS for RNA extraction and Bcl11a quantification. Additionally, flow cytometry was used to analyse fetal liver from E18.5 embryos. Single cell suspensions were stained with IgM-FITC (Clone Il-41; eBioscience), CD19-PerCP-Cy5.5, (Clone 1D3; eBioscience), CD43-PE (Clone S7; eBioscience), AA4.1-PE-Cy7 (Clone AA4.1; BD Biosciences), B220-APC, (RA3-6B2; Biolegend), and DAPI (Invitrogen). For adult haematopoietic assays, peripheral blood was obtained from the tail vein of 4-week-old male and female mice. Blood was collected in EDTA-coated tubes, red HbF level (MFI) 10 28 . b, Ranked enhancers in mouse erythroid precursors by H3K27ac signal intensity 55, 56 , with super-enhancers shaded. Super-enhancer associated genes are indicated by Venn diagram. c, Strategy to knock-in by homology-directed repair the fluorescent protein mCherry into the mouse embryonic globin Hbb-y locus (encoding the ey embryonic globin chain). d, Distribution of NGG and NAG PAM sgRNAs mapped to genomic cleavage position with vertical lines representing cleavage sites for sgRNAs mapped to plus and minus strands. e, Distance to adjacent genomic cleavage position for NGG (left) and NAG (right) PAM sgRNAs. f, Representation of the 1,271 NGG and NAG sgRNAs within the plasmid pool by deep sequencing. The median was 735 normalized reads and the 10th and 90th percentiles (indicated by the vertical dotted lines) ranged from 393 to 1,240 normalized reads. g, Library composition by target sequence and PAM restriction. h, mCherry expression upon exposure to Cas9 and an individual NGG sgRNA targeting Bcl11a exon 2 in MEL ey:mCherry reporter cells. i, ey:mCherry sort of library transduced cells. j, Control sgRNA enrichment. Boxes demonstrate 25th, median and 75th percentiles and whiskers minimum and maximum values. ****P , 0.0001. k, Enrichment scores of NGG sgRNAs between four biological replicates. enhancer. a-c, HMM segmentation of active functional states at m155, m158 and m162 orthologues. HbF enrichment scores are shown as grey lines and circles with the blue line representing smoothed enrichment score. DNase I sequencing from mouse fetal liver erythroid precursors 28 . PhyloP (scale from 23.3 to 2.1) and PhastCons (from 0 to 1) estimates of evolutionary conservation among 30 vertebrates are shown. d, Top: Bcl11a expression determined by RT-qPCR displayed as a heat map in 108 hemizygous m162 orthologue deletion clones ordered by genomic position of deletion midpoint. Each bar demonstrates the genomic position of the deletion breakpoints and the associated colour demonstrates the level of Bcl11a expression. Bottom: Bcl11a expression determined by RT-qPCR in 108 hemizygous m162 orthologue deletion clones. Per nucleotide mean effect size was calculated as the mean fold change in Bcl11a expression from all clones in which that nucleotide was deleted. Grey shading represents one s.d. The Bcl11a expression data are shown with same x axis as in panel c immediately above.
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